Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA.
Department of Pathology, Wayne State University School of Medicine/Detroit Medical Center, Detroit, MI, USA.
Cancer Lett. 2024 Nov 1;604:217275. doi: 10.1016/j.canlet.2024.217275. Epub 2024 Sep 24.
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy, with limited therapeutic options. Here, we evaluated the role of regulator of chromosome condensation 1 (RCC1) in PDAC. RCC1 functions as a guanine exchange factor for GTP-binding nuclear protein Ran (Ran) GTPase and is involved in nucleocytoplasmic transport. RCC1 RNA expression is elevated in PDAC tissues compared to normal pancreatic tissues and correlates with poor prognosis. RCC1 silencing by RNAi and CRISPR-Cas9 knockout (KO) results in reduced proliferation in 2-D and 3-D cell cultures. RCC1 knockdown (KD) reduced migration and clonogenicity, enhanced apoptosis, and altered cell cycle progression in human PDAC and murine cells from LSL-Kras; LSL-Trp53; Pdx1-Cre (KPC) tumors. Mechanistically, RCC1 KO shows widespread transcriptomic alterations including regulation of PTK7, a co-receptor of the Wnt signaling pathway. RCC1 KD disrupted subcellular Ran localization and the Ran gradient. Nuclear and cytosolic proteomics revealed altered subcellular proteome localization in Rcc1 KD KPC-tumor-derived cells and several altered metabolic biosynthesis pathways. In vivo, RCC1 KO cells show reduced tumor growth potential when injected as sub-cutaneous xenografts. Finally, RCC1 KD sensitized PDAC cells to gemcitabine chemotherapy treatment. This study reveals the role of RCC1 in pancreatic cancer as a novel molecular vulnerability that could be exploited to enhance therapeutic response.
胰腺导管腺癌 (PDAC) 是一种高度致命的恶性肿瘤,治疗选择有限。在这里,我们评估了染色体凝聚调节因子 1 (RCC1) 在 PDAC 中的作用。RCC1 作为 GTP 结合核蛋白 Ran(Ran)GTPase 的鸟嘌呤交换因子发挥作用,参与核质转运。与正常胰腺组织相比,PDAC 组织中 RCC1 RNA 表达升高,与预后不良相关。通过 RNAi 和 CRISPR-Cas9 敲除 (KO) 沉默 RCC1 可导致 2-D 和 3-D 细胞培养中的增殖减少。RCC1 敲低 (KD) 降低了人 PDAC 和 LSL-Kras;LSL-Trp53;Pdx1-Cre (KPC) 肿瘤来源的鼠细胞的迁移和集落形成能力,增强了细胞凋亡,并改变了细胞周期进程。从机制上讲,RCC1 KO 显示出广泛的转录组改变,包括 Wnt 信号通路共受体 PTK7 的调节。RCC1 KD 破坏了 Ran 定位和 Ran 梯度的亚细胞。核质和细胞质蛋白质组学揭示了 Rcc1 KD KPC 肿瘤衍生细胞中亚细胞蛋白质组定位的改变,以及几种改变的代谢生物合成途径。在体内,作为皮下异种移植注射时,RCC1 KO 细胞显示出降低的肿瘤生长潜力。最后,RCC1 KD 使 PDAC 细胞对吉西他滨化疗治疗敏感。这项研究揭示了 RCC1 在胰腺癌中的作用,作为一种新的分子脆弱性,可用于增强治疗反应。